Статті в журналах: "Mesenchymal stem cell therapy"

1

Mundra, Vaibhav, Ivan C. Gerling, and Ram I. Mahato. "Mesenchymal Stem Cell-Based Therapy." Molecular Pharmaceutics 10, no. 1 (December 24, 2012): 77–89. http://dx.doi.org/10.1021/mp3005148.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Choi, Yeong-Hoon, Andreas Kurtz, and Christof Stamm. "Mesenchymal Stem Cells for Cardiac Cell Therapy." Human Gene Therapy 22, no. 1 (January 2011): 3–17. http://dx.doi.org/10.1089/hum.2010.211.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Mihaylova, Zornitsa. "Stem cells and mesenchymal stem cell markers." International Journal of Medical Science and Clinical invention 6, no. 08 (August 6, 2019): 4544–47. http://dx.doi.org/10.18535/ijmsci/v6i8.03.

Повний текст джерела

Анотація:

Stem cells are undifferentiated cell type characterized by colonogenic ability, self-renewal and multi-lineage differentiation. They are classified into the following categories: embryonic stem cells [ESC], somatic stem cells [or adult stem cells] and induced pluripotent stem cells [iPSC]. Stem cells represent area of interest for wide range of scientists, as they are promising tool for regenerative therapy. Their differentiation ability is significantly affected by various factors of the local environment. Additional research will provide more information about the optimal cell culture conditions when stem cells are cultivated for clinical purpose, to avoid side effects like uncontrolled cell proliferation and premature differentiation.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Haseli, Mahsa, and Akbar Esmaeili. "Concerns About Mesenchymal Stem Cell Therapy." International Clinical Neuroscience Journal 8, no. 1 (December 30, 2020): 1–2. http://dx.doi.org/10.34172/icnj.2021.01.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Dazzi, Francesco, and Nicole J. Horwood. "Potential of mesenchymal stem cell therapy." Current Opinion in Oncology 19, no. 6 (November 2007): 650–55. http://dx.doi.org/10.1097/cco.0b013e3282f0e116.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Horwitz, E. M. "Mesenchymal and nonhematopoietic stem-cell therapy." Cytotherapy 4, no. 6 (October 2002): 501. http://dx.doi.org/10.1080/146532402761624610.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Afizah, Hassan, and James Hoi Po Hui. "Mesenchymal stem cell therapy for osteoarthritis." Journal of Clinical Orthopaedics and Trauma 7, no. 3 (July 2016): 177–82. http://dx.doi.org/10.1016/j.jcot.2016.06.006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Abbasi, Ardeshir. "Mesenchymal stem cells: applications in immuno-cell therapy." Journal of Immunological Sciences 2, no. 4 (August 1, 2018): 1–3. http://dx.doi.org/10.29245/2578-3009/2018/4.1149.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Samper, E., A. Diez-Juan, J. A. Montero, and P. Sepúlveda. "Cardiac Cell Therapy: Boosting Mesenchymal Stem Cells Effects." Stem Cell Reviews and Reports 9, no. 3 (February 16, 2012): 266–80. http://dx.doi.org/10.1007/s12015-012-9353-z.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Brown, Christina, Christina McKee, Shreeya Bakshi, Keegan Walker, Eryk Hakman, Sophia Halassy, David Svinarich, Robert Dodds, Chhabi K. Govind, and G. Rasul Chaudhry. "Mesenchymal stem cells: Cell therapy and regeneration potential." Journal of Tissue Engineering and Regenerative Medicine 13, no. 9 (July 25, 2019): 1738–55. http://dx.doi.org/10.1002/term.2914.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Gadkari, Rishali, Longmei Zhao, Takele Teklemariam, and Basil M. Hantash. "Human embryonic stem cell derived-mesenchymal stem cells: an alternative mesenchymal stem cell source for regenerative medicine therapy." Regenerative Medicine 9, no. 4 (July 2014): 453–65. http://dx.doi.org/10.2217/rme.14.13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Mifflin, R. C., I. V. Pinchuk, J. I. Saada, and D. W. Powell. "Intestinal myofibroblasts: targets for stem cell therapy." American Journal of Physiology-Gastrointestinal and Liver Physiology 300, no. 5 (May 2011): G684—G696. http://dx.doi.org/10.1152/ajpgi.00474.2010.

Повний текст джерела

Анотація:

The subepithelial intestinal myofibroblast is an important cell orchestrating many diverse functions in the intestine and is involved in growth and repair, tumorigenesis, inflammation, and fibrosis. The myofibroblast is but one of several α-smooth muscle actin-positive (α-SMA+) mesenchymal cells present within the intestinal lamina propria, including vascular pericytes, bone marrow-derived stem cells (mesenchymal stem cells or hematopoietic stem cells), muscularis mucosae, and the lymphatic pericytes (colon) and organized smooth muscle (small intestine) associated with the lymphatic lacteals. These other mesenchymal cells perform many of the functions previously attributed to subepithelial myofibroblasts. This review discusses the definition of a myofibroblast and reconsiders whether the α-SMA+ subepithelial cells in the intestine are myofibroblasts or other types of mesenchymal cells, i.e., pericytes. Current information about specific, or not so specific, molecular markers of lamina propria mesenchymal cells is reviewed, as well as the origins of intestinal myofibroblasts and pericytes in the intestinal lamina propria and their replenishment after injury. Current concepts and research on stem cell therapy for intestinal inflammation are summarized. Information about the stem cell origin of intestinal stromal cells may inform future stem cell therapies to treat human inflammatory bowel disease (IBD).

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Zahran F, Zahran F., El-Ghareb M. El-Ghareb M, Nashwa Barakat, and El-Naggar I. El-Naggar I. "Biochemical Evaluation to Mesenchymal Stem Cells Therapy of Renal Tubulointerstitial Injury." Indian Journal of Applied Research 3, no. 10 (October 1, 2011): 1–5. http://dx.doi.org/10.15373/2249555x/oct2013/6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Gupta, PD. "Menstrual Blood Mesenchymal Stem Cells: Boon in Therapeutics." Biotechnology and Bioprocessing 2, no. 4 (May 28, 2021): 01–06. http://dx.doi.org/10.31579/2766-2314/032.

Повний текст джерела

Анотація:

Stem cell therapy gained momentum for the past three decades in therapeutics. Alternative strategies are indispensable for the treatment of many diseases in the present scenario due to side effects of synthetic chemicals as drugs. Mesenchymal cells of different origin have been in use with good results, though ethical issues and limited availability is a drawback. Novel menstrual blood mesenchymal stems cells prove to be a wealth out of waste is a boon in therapeutics. In this review we bring a bird’s eye view of different diseases treated with menstrual blood mesenchymal stem cells with positive results. Evolution in the use of these cells more and more will be a big relief to many who suffer with side effects of drugs.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

An, JH, KB Kim, SC Kwon, HJ Kim, MO Ryu, YI Oh, JO Ahn, and HY Youn. "Canine adipose tissue-derived mesenchymal stem cell therapy in a dog with renal Fanconi syndrome." Veterinární Medicína 67, No. 4 (February 16, 2022): 206–11. http://dx.doi.org/10.17221/213/2020-vetmed.

Повний текст джерела

Анотація:

Renal Fanconi syndrome (RFS) affects the proximal tubular resorption in the nephrons. This causes excessive loss of key solutes through the urine. In a canine patient, we successfully managed the renal tubular acidosis and proteinuria caused by RFS via transplantation of canine adipose tissue-derived mesenchymal stem cells (cAT-MSCs). cAT-MSCs were administered ten times at intervals of 2–4 weeks. The post-therapy check-up revealed that the cAT-MSC treatment improved the renal tubular acidosis and proteinuria. Hence, a cAT-MSC transplant may be considered as an adjuvant therapy in veterinary medicine to initiate and maintain relief of RFS-induced acidosis and proteinuria.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Kin, Kyohei, Takao Yasuhara, and Isao Date. "Encapsulation of Mesenchymal Stem Cells: Dissecting the Underlying Mechanism of Mesenchymal Stem Cell Transplantation Therapy." Neuroscience Insights 15 (January 2020): 263310552095906. http://dx.doi.org/10.1177/2633105520959064.

Повний текст джерела

Анотація:

Mesenchymal stem cells (MSCs) are widely considered good candidates for cell transplantation therapy. Various central nervous system disorders have been suggested as suitable targets for MSC transplantation therapy. In this context, a great deal of basic and clinical research has been conducted to explore its clinical uses. Although depression is one of the most common diseases in the world, the response rate to the currently available treatment is insufficient and new treatments are much needed. Despite the fact that MSC transplantation therapy has the potential to elicit an antidepressant effect, few studies have been conducted on this topic to date and the underlying mechanism remains poorly understood. To address the development of a new treatment for depression, we evaluated the effect of MSCs using the encapsulation technique and Wistar-Kyoto rats. Encapsulation enables dissection of the complicated underlying mechanism of MSC transplantation therapy. Wistar-Kyoto rats that exhibit treatment-resistant depressive-like behaviors allow us to compare the effect of MSCs with that of conventional antidepressant treatment. In this commentary, we briefly summarize our recent published results and discuss future research prospects.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Kitada, Masaaki, and Mari Dezawa. "Parkinson's Disease and Mesenchymal Stem Cells: Potential for Cell-Based Therapy." Parkinson's Disease 2012 (2012): 1–9. http://dx.doi.org/10.1155/2012/873706.

Повний текст джерела

Анотація:

Cell transplantation is a strategy with great potential for the treatment of Parkinson's disease, and many types of stem cells, including neural stem cells and embryonic stem cells, are considered candidates for transplantation therapy. Mesenchymal stem cells are a great therapeutic cell source because they are easy accessible and can be expanded from patients or donor mesenchymal tissues without posing serious ethical and technical problems. They have trophic effects for protecting damaged tissues as well as differentiation ability to generate a broad spectrum of cells, including dopamine neurons, which contribute to the replenishment of lost cells in Parkinson's disease. This paper focuses mainly on the potential of mesenchymal stem cells as a therapeutic cell source and discusses their potential clinical application in Parkinson's disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Park, You Jeong, Kuniyasu Niizuma, Maxim Mokin, Mari Dezawa, and Cesar V. Borlongan. "Cell-Based Therapy for Stroke." Stroke 51, no. 9 (September 2020): 2854–62. http://dx.doi.org/10.1161/strokeaha.120.030618.

Повний текст джерела

Анотація:

Stem cell-based regenerative therapies may rescue the central nervous system following ischemic stroke. Mesenchymal stem cells exhibit promising regenerative capacity in in vitro studies but display little to no incorporation in host tissue after transplantation in in vivo models of stroke. Despite these limitations, clinical trials using mesenchymal stem cells have produced some functional benefits ascribed to their ability to modulate the host’s inflammatory response coupled with their robust safety profile. Regeneration of ischemic brain tissue using stem cells, however, remains elusive in humans. Multilineage-differentiating stress-enduring (Muse) cells are a distinct subset of mesenchymal stem cells found sporadically in connective tissue of nearly every organ. Since their discovery in 2010, these endogenous reparative stem cells have been investigated for their therapeutic potential against a variety of diseases, including acute myocardial infarction, stroke, chronic kidney disease, and liver disease. Preclinical studies have exemplified Muse cells’ unique ability mobilize, differentiate, and engraft into damaged host tissue. Intravenously transplanted Muse cells in mouse lacunar stroke models afforded functional recovery and long-term engraftment into the host neural network. This mini-review article highlights these biological properties that make Muse cells an exceptional candidate donor source for cell therapy in ischemic stroke. Elucidating the mechanism behind the therapeutic potential of Muse cells will undoubtedly help optimize stem cell therapy for stroke and advance the field of regenerative medicine.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Vija, L., D. Farge, J. F. Gautier, P. Vexiau, C. Dumitrache, A. Bourgarit, F. Verrecchia, and J. Larghero. "Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes." Diabetes & Metabolism 35, no. 2 (April 2009): 85–93. http://dx.doi.org/10.1016/j.diabet.2008.10.003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Jin, Yuan-Zhe, and Jae Hyup Lee. "Mesenchymal Stem Cell Therapy for Bone Regeneration." Clinics in Orthopedic Surgery 10, no. 3 (2018): 271. http://dx.doi.org/10.4055/cios.2018.10.3.271.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Liz G. Alves, Ana, Armando de Mattos Carvalho, and Carlos A. Hussni. "Mesenchymal Stem Cell Therapy for Equine Tendinitis." Recent Patents on Regenerative Medicine 3, no. 2 (February 1, 2013): 103–10. http://dx.doi.org/10.2174/2210296511303020002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Rahman, Fazliny Bt Abd. "Mesenchymal Stem Cell Therapy and COVID-19." International Journal of Biomedicine 12, no. 3 (September 5, 2022): 329–38. http://dx.doi.org/10.21103/article12(3)_ra1.

Повний текст джерела

Анотація:

The coronavirus disease 2019 (COVID-19) caused by the novel, severe acute respiratory coronavirus 2 (SARS-CoV-2) has been spreading since late 2019 and has infected more than 360 million people worldwide. Infected individuals often develop severe illnesses, such as hypoxic respiratory failure and acute respiratory distress syndrome, which can lead to multiple organ failure. To manage the COVID-19 pandemic, vaccination programs have been conducted around the globe. In addition to supportive and antiviral medications, much attention has been focused on immunotherapies aimed at reducing pathological changes in the lungs. Currently, mesenchymal stem cells (MSCs) have received extensive attention as an option in treating COVID-19 because of their immunomodulatory, anti-inflammatory, and regenerative properties. This article discusses how MSCs play a major role in the battle against COVID-19, their pathological characteristics, their safety, and their possible effectiveness in treating the disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Hernández, A. E., and E. García. "Mesenchymal Stem Cell Therapy for Alzheimer’s Disease." Stem Cells International 2021 (September 1, 2021): 1–12. http://dx.doi.org/10.1155/2021/7834421.

Повний текст джерела

Анотація:

Alzheimer’s disease (AD) is a neurodegenerative disease responsible for 60-70% of the 50 million cases of dementia worldwide. It is characterized by neuronal cell death, shrinkage of brain tissue, and progressive cognitive, motor, and behavioral impairment, which often leads to death. Although current treatment has helped improve the patient’s quality of life, it has not been able to alter the underlying disease pathology of AD. Studies have shown that mesenchymal stem cells (MSCs)—a group of multipotent stem cells—have the ability to stimulate neuroregeneration and inhibit disease progression. More recently, extracellular vesicles (EVs) from cytokine-preconditioned MSCs have also shown to induce immunomodulatory and neuroprotective effects in AD models. This review will aim to compile pertinent preclinical AD research on transgenic mice as well as clinical trials on MSC-based therapy from diverse sources.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

da Silva, Jaqueline S., Renata G. J. Gonçalves, Juliana F. Vasques, Bruna S. Rocha, Bianca Nascimento-Carlos, Tadeu L. Montagnoli, Rosália Mendez-Otero, Mauro P. L. de Sá, and Gisele Zapata-Sudo. "Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy." Cells 11, no. 2 (January 11, 2022): 240. http://dx.doi.org/10.3390/cells11020240.

Повний текст джерела

Анотація:

The incidence and prevalence of diabetes mellitus (DM) are increasing worldwide, and the resulting cardiac complications are the leading cause of death. Among these complications is diabetes-induced cardiomyopathy (DCM), which is the consequence of a pro-inflammatory condition, oxidative stress and fibrosis caused by hyperglycemia. Cardiac remodeling will lead to an imbalance in cell survival and death, which can promote cardiac dysfunction. Since the conventional treatment of DM generally does not address the prevention of cardiac remodeling, it is important to develop new alternatives for the treatment of cardiovascular complications induced by DM. Thus, therapy with mesenchymal stem cells has been shown to be a promising approach for the prevention of DCM because of their anti-apoptotic, anti-fibrotic and anti-inflammatory effects, which could improve cardiac function in patients with DM.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Yong, Kar Wey, Jane Ru Choi, Mehdi Mohammadi, Alim P. Mitha, Amir Sanati-Nezhad, and Arindom Sen. "Mesenchymal Stem Cell Therapy for Ischemic Tissues." Stem Cells International 2018 (October 8, 2018): 1–11. http://dx.doi.org/10.1155/2018/8179075.

Повний текст джерела

Анотація:

Ischemic diseases such as myocardial infarction, ischemic stroke, and critical limb ischemia are immense public health challenges. Current pharmacotherapy and surgical approaches are insufficient to completely heal ischemic diseases and are associated with a considerable risk of adverse effects. Alternatively, human mesenchymal stem cells (hMSCs) have been shown to exhibit immunomodulation, angiogenesis, and paracrine secretion of bioactive factors that can attenuate inflammation and promote tissue regeneration, making them a promising cell source for ischemic disease therapy. This review summarizes the pathogenesis of ischemic diseases, discusses the potential therapeutic effects and mechanisms of hMSCs for these diseases, and provides an overview of challenges of using hMSCs clinically for treating ischemic diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Yeung, Winnie Wan-Yin, and Chak-Sing Lau. "Mesenchymal Stem Cell Therapy for rheumatic diseases." Hong Kong Bulletin on Rheumatic Diseases 16, no. 1 (August 1, 2016): 6–10. http://dx.doi.org/10.1515/hkbrd-2016-0002.

Повний текст джерела

Анотація:

AbstractMesenchymal stem cell therapy (MSCT) is an innovative treatment for rheumatic diseases. Underlying mechanism of how MSCT works in rheumatic diseases are still uncertain and with various hypotheses. Animal studies in MSCT show conflicting results mainly attributed by the differences in administration methods of MSCT, types of MSC use and randomization procedures. Human studies of MSCT are so far small scale but with satisfactory results in patients with systemic lupus erythematosus (SLE). Human studies of MSCT, however, showed less rewarding results in patients with rheumatoid arthritis (RA) and systemic sclerosis (SSc). Larger scale studies are needed to confirm the efficiency of MSCT as well as the safety profile in human use.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Chuang, Hong-Meng, Tina Emily Shih, Kang-Yun Lu, Sheng-Feng Tsai, Horng-Jyh Harn, and Li-Ing Ho. "Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis." Cell Transplantation 27, no. 11 (July 11, 2018): 1581–87. http://dx.doi.org/10.1177/0963689718787501.

Повний текст джерела

Анотація:

Although the clinical application of new drugs has been shown to be effective in slowing disease progression and improving the quality of life in patients with pulmonary fibrosis, the damaged lung tissue does not recover with these drugs. Thus, there is an urgent need to establish regenerative therapy, such as stem cell therapy or tissue engineering. Moreover, the clinical application of mesenchymal stem cell (MSC) therapy has been shown to be safe in humans with idiopathic pulmonary fibrosis (IPF). It seems that a combination of MSC transplantation and pharmaceutical therapy might have additional benefits; however, the experimental design for its efficacy is still lacking. In this review, we provide an overview of the mechanisms that were identified when IPF was treated with MSC transplantation or new drugs. To maximize the therapeutic effect, we suggest that MSC transplantation is combined with drug application for synergistic effects. This review provides clinicians and scientists with the most efficient medical options, in the hope that this will spur on future research and lead to an eventual cure for this disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Carvalho, Katherine Athayde Teixeira de, Gustav Steinhoff, and Juan Carlos Chachques. "Mesenchymal Stem Cell Therapy in Nonhematopoietic Diseases." Stem Cells International 2015 (2015): 1–2. http://dx.doi.org/10.1155/2015/676903.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Hocking, Anne M. "Mesenchymal Stem Cell Therapy for Cutaneous Wounds." Advances in Wound Care 1, no. 4 (August 2012): 166–71. http://dx.doi.org/10.1089/wound.2011.0294.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Chen, Lukui, Rong Qiu, and Qiang Xu. "Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases." Journal of Nanoscience and Nanotechnology 14, no. 1 (January 1, 2014): 969–75. http://dx.doi.org/10.1166/jnn.2014.9126.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Magne, David, Claire Vinatier, Marion Julien, Pierre Weiss, and Jérôme Guicheux. "Mesenchymal stem cell therapy to rebuild cartilage." Trends in Molecular Medicine 11, no. 11 (November 2005): 519–26. http://dx.doi.org/10.1016/j.molmed.2005.09.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Shukla, Sachin, Fatemeh Tavakkoli, Vivek Singh, and Virender Singh Sangwan. "Mesenchymal stem cell therapy for corneal diseases." Expert Opinion on Orphan Drugs 4, no. 9 (August 5, 2016): 917–26. http://dx.doi.org/10.1080/21678707.2016.1215906.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Lopes, João Pedro, António Fiarresga, Pedro Silva Cunha, Joana Feliciano, and Rui Cruz Ferreira. "Mesenchymal stem cell therapy in heart disease." Revista Portuguesa de Cardiologia (English Edition) 32, no. 1 (January 2013): 43–47. http://dx.doi.org/10.1016/j.repce.2012.11.005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Gnecchi, Massimiliano, Patrizia Danieli, and Elisabetta Cervio. "Mesenchymal stem cell therapy for heart disease." Vascular Pharmacology 57, no. 1 (August 2012): 48–55. http://dx.doi.org/10.1016/j.vph.2012.04.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Eom, Young Woo, Kwang Yong Shim, and Soon Koo Baik. "Mesenchymal stem cell therapy for liver fibrosis." Korean Journal of Internal Medicine 30, no. 5 (August 27, 2015): 580–89. http://dx.doi.org/10.3904/kjim.2015.30.5.580.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Lee, Eun Joo. "Mesenchymal Stem Cell Therapy in Pulmonary Disease." Korean Journal of Medicine 89, no. 5 (November 1, 2015): 522–26. http://dx.doi.org/10.3904/kjm.2015.89.5.522.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Smith, Roger K. W. "Mesenchymal stem cell therapy for equine tendinopathy." Disability and Rehabilitation 30, no. 20-22 (January 2008): 1752–58. http://dx.doi.org/10.1080/09638280701788241.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Carter, Janet E., and Edward H. Schuchman. "Mesenchymal stem cell therapy for neurodegenerative disease." Neurobiology of Aging 21 (May 2000): 152. http://dx.doi.org/10.1016/s0197-4580(00)82022-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Huang, Liyi, Chenying Fu, Feng Xiong, Chengqi He, and Quan Wei. "Stem Cell Therapy for Spinal Cord Injury." Cell Transplantation 30 (January 1, 2021): 096368972198926. http://dx.doi.org/10.1177/0963689721989266.

Повний текст джерела

Анотація:

Traumatic spinal cord injury (SCI) results in direct and indirect damage to neural tissues, which results in motor and sensory dysfunction, dystonia, and pathological reflex that ultimately lead to paraplegia or tetraplegia. A loss of cells, axon regeneration failure, and time-sensitive pathophysiology make tissue repair difficult. Despite various medical developments, there are currently no effective regenerative treatments. Stem cell therapy is a promising treatment for SCI due to its multiple targets and reactivity benefits. The present review focuses on SCI stem cell therapy, including bone marrow mesenchymal stem cells, umbilical mesenchymal stem cells, adipose-derived mesenchymal stem cells, neural stem cells, neural progenitor cells, embryonic stem cells, induced pluripotent stem cells, and extracellular vesicles. Each cell type targets certain features of SCI pathology and shows therapeutic effects via cell replacement, nutritional support, scaffolds, and immunomodulation mechanisms. However, many preclinical studies and a growing number of clinical trials found that single-cell treatments had only limited benefits for SCI. SCI damage is multifaceted, and there is a growing consensus that a combined treatment is needed.

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Zahran F, Zahran F., El-Ghareb M. El-Ghareb M, and Nabil A. Nabil A. "Bone Marrow Derived Mesenchymal Stem Cells As A Therapy for Renal Injury." Indian Journal of Applied Research 4, no. 4 (October 1, 2011): 11–16. http://dx.doi.org/10.15373/2249555x/apr2014/3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Wang, Shihua, Pengchao Xu, Xiaoxia Li, Xiaodong Su, Yunfei Chen, Li Wan, Linyuan Fan, Kan Yin, Yan Liu, and Robert Chunhua Zhao. "Mesenchymal Stem Cells and Cell Therapy for Bone Repair." Current Molecular Pharmacology 9, no. 4 (November 9, 2016): 289–99. http://dx.doi.org/10.2174/1874467208666150928153758.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Ozawa, Keiya, Kazuya Sato, Iekuni Oh, Katsutoshi Ozaki, Ryosuke Uchibori, Yoko Obara, Yuji Kikuchi, et al. "Cell and gene therapy using mesenchymal stem cells (MSCs)." Journal of Autoimmunity 30, no. 3 (May 2008): 121–27. http://dx.doi.org/10.1016/j.jaut.2007.12.008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Wei, Xin, Xue Yang, Zhi-peng Han, Fang-fang Qu, Li Shao, and Yu-fang Shi. "Mesenchymal stem cells: a new trend for cell therapy." Acta Pharmacologica Sinica 34, no. 6 (June 2013): 747–54. http://dx.doi.org/10.1038/aps.2013.50.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Kuo, Tom K., Jennifer H. Ho, and Oscar K. Lee. "Mesenchymal Stem Cell Therapy for Nonmusculoskeletal Diseases: Emerging Applications." Cell Transplantation 18, no. 9 (September 2009): 1013–28. http://dx.doi.org/10.3727/096368909x471206.

Повний текст джерела

Анотація:

Mesenchymal stem cells are stem/progenitor cells originated from the mesoderm and can different into multiple cell types of the musculoskeletal system. The vast differentiation potential and the relative ease for culture expansion have established mesenchymal stem cells as the building blocks in cell therapy and tissue engineering applications for a variety of musculoskeletal diseases, including repair of fractures and bone defects, cartilage regeneration, treatment of osteonecrosis of the femoral head, and correction of genetic diseases such as osteogenesis imperfect. However, research in the past decade has revealed differentiation potentials of mesenchymal stem cells beyond lineages of the mesoderm, suggesting broader applications than originally perceived. In this article, we review the recent developments in mesenchymal stem cell research with respect to their emerging properties and applications in nonmusculoskeletal diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Xu, Zhongjuan, Xingzhi Liu, Yu Wei, Zhe Zhao, Junjun Cao, Yong Qiao, Yanzhen Yu, Junjie Zhong, and Guangli Suo. "Mesenchymal stem cell spheroids: potential cell materials for cell therapy." STEMedicine 2, no. 5 (December 13, 2020): e67. http://dx.doi.org/10.37175/stemedicine.v2i5.67.

Повний текст джерела

Анотація:

Mesenchymal stromal/stem cells (MSCs) have been applied in clinical trials with an increasing number in recent years. MSCs showed their great potentials in regenerative medicine for their extensive sources, multilineage differentiation potential, low immunogenicity and self-renewal ability. However, the clinical application of MSCs still confronts many challenges including the requirement of large quantity of cells, low survival ability in vivo and the loss of main original characteristics due to two-dimensional (2D) culture although it is beneficial to cells fast expansion. Three-dimensional (3D) culture artificially creates an environment that permits cells to grow or interact with their surroundings in all three dimensions. Therefore, 3D culture was widely regarded as a more preferable and closer physiological microenvironment for cells growth. Recently, many different 3D spheroid culture methods have been developed to optimize MSCs biological characteristics to meet the demand of regenerative medicine. In this review, we comprehensively discussed the merits and demerits of different spheroid formation methods, expounded the mechanisms of spheroid formation and its microenvironment, and illustrated their optimized biological functions and the pre-clinical applications in various tissue injury and regeneration. In the end, we prospected the trends of this research field and proposed the key problems needed to be solved in the future.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Fathollahi, A., N. B. Gabalou, and S. Aslani. "Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder." Lupus 27, no. 7 (April 9, 2018): 1053–64. http://dx.doi.org/10.1177/0961203318768889.

Повний текст джерела

Анотація:

Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disorder with involvement of several organs and systems such as the kidney, lung, brain and the hematopoietic system. As the most prevailing organ manifestation, lupus nephritis is the major cause of mortality and morbidity in SLE patients. The most classically and widely administered immunosuppressive medications, namely corticosteroids and cyclophosphamide, have eventuated in a remarkable amelioration in disease complications over the last few years and reduced the progression to end-stage multiorgan failure. Mesenchymal stem cells (MSCs) are considered as non-hematopoietic and multipotential progenitor cells, which are able to differentiate into multiple cell lineages such as chondrocytes, osteoblasts, myoblasts, endothelial cells, adipocytes, neuron-like cells, hepatocytes and cardiomyocytes. MSCs from SLE patients have demonstrated defects such as aberrant cytokine production. Moreover, impaired phenotype, growth and immunomodulatory functions of MSCs from patients with SLE in comparison to healthy controls have been reported. Therefore, it is hypothesized that SLE is potentially an MSC-mediated disease and, as a result, allogeneic rather than autologous MSC transplantation can be argued to be a potentially advantageous therapy for patients with SLE. On the other hand, the MSC senescence phenomenon may meet the current therapeutic approaches with challenges and demand more attention. Here, we discuss MSC transplantations to date in animal models and humans and focus on the MSC senescence complications in SLE patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Carvalho, Juliana L., Vinicius B. A. Braga, Marcos B. Melo, Ana Carolina D. A. Campos, Maira S. Oliveira, Dawidson A. Gomes, Anderson J. Ferreira, Robson A. S. Santos, and Alfredo M. Goes. "Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction." Journal of Cellular and Molecular Medicine 17, no. 5 (March 14, 2013): 617–25. http://dx.doi.org/10.1111/jcmm.12036.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Bedini, Gloria, Anna Bersano, Elisa R. Zanier, Francesca Pischiutta, and Eugenio A. Parati. "Mesenchymal Stem Cell Therapy in Intracerebral Haemorrhagic Stroke." Current Medicinal Chemistry 25, no. 19 (May 30, 2018): 2176–97. http://dx.doi.org/10.2174/0929867325666180111101410.

Повний текст джерела

Анотація:

Background: Spontaneous intracerebral haemorrhage (ICH) is a relatively common fatal disease, with an overall global incidence estimated at 24.6 per 100,000 person- years. Given the high degree of morbidity and mortality associated with ICH, therapies that may have neuroprotective effects are of increasing interest to clinicians. In this last context, cell therapies offer the promise of improving the disease course which cannot be addressed adequately by existing treatments. Objective: The aim of this review is to evaluate the protective effects and molecular mechanisms of mesenchymal stem cells (MSCs) on haemorrhagic brain following ICH. We also discuss possible emerging therapeutic approaches worth of further research. Methods and Results: The available literature on the therapeutic potential of MSCs in ICH animal models clearly demonstrated that MSCs enhance the functional recovery and reduce the volume of the infarct size exerting anti-inflammatory and angiogenic properties. However, the quality of the original articles investigating the efficacy of stem cell therapies in ICH animal models is still poor and the lack of ICH clinical trial does not permit to reach any relevant conclusions. Conclusion: Further studies have to be implemented in order to achieve standardized methods of MSCs isolation, characterization and administration to improve ICH treatments with MSCs or MSC-derived products.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Hui , James HP. "Mesenchymal stem cell therapy for injured growth plate." Frontiers in Bioscience S5, no. 2 (2013): 774–85. http://dx.doi.org/10.2741/s407.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Mastri, Michalis. "Enhancing the efficacy of mesenchymal stem cell therapy." World Journal of Stem Cells 6, no. 2 (2014): 82. http://dx.doi.org/10.4252/wjsc.v6.i2.82.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Mesenchymal stem cell therapy"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями